Using AI in Pharma R&D and Clinical Testing—Regulatory and Legal Issues for the US Landscape

In this session, partners Kathleen Sanzo, Jacqueline Berman, Nancy Yamaguchi, and Jitsuro Morishita will explain how the biopharma industry is using AI to increase efficiencies during the drug development process, explore the legal and regulatory implications of AI’s application to clinical trials, and discuss the potential future of AI in the Food and Drug Administration’s drug and biologic divisions.